-transparent.png){kind=logo}
The objective of the present article is to revise the biochemical and pharmacological knowledge of the leukotrienes, including the enzymatic and cellular processes that participate in its synthesis. The half-filled biological effects through diverse receptors as the cystenil-leukotrienes, have a primordial participation in the physiopathology of the asthma. The 5-lipooxigenase inhibitor, 5-lipooxygenase-activating protein antagonist, and cystenil-leukotrienes, are three classes of new modulators for clinical use. Their effect has been revised in diverse clinical models of asthma, as the one induced by allergens, exercise, aspirin and in multicenter asthma trials are reviewed. The conclusions in general guide to that their pharmacology and the clinical experience that one has, contain them as a new therapeutic role in the treatment of the asthma.
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
January 2003,
Advances in experimental medicine and biology,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
January 1991,
Advances in prostaglandin, thromboxane, and leukotriene research,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
May 1993,
Clinical science (London, England : 1979),
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
May 1984,
Recenti progressi in medicina,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
August 1984,
Allergy,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
July 2002,
Medical journal, Armed Forces India,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
March 1994,
Annals of allergy,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
June 2008,
Mini reviews in medicinal chemistry,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
June 2001,
Current opinion in pharmacology,
M Ruiz Fernández, and
G Flores Sandoval, and
M Orea Solano
January 1989,
Revue des maladies respiratoires,
